Investor Announcements - 2011

EKF Diagnostics has been awarded a contract in Mexico for 3,500 HemoPoint H2 haemoglobin testing devices.

EKF Diagnostics Holdings plc announces its unaudited interim results for the six month period ended 30 June 2011, a period of transition, investment and progression.

EKF Diagnostics announces that it has entered into a conditional distribution agreement with Alere Inc.

Proposed acquisition of the entire issued share capital of Stanbio Laboratory L.P. 

Quotient Diagnostics has received approval from China’s SFDA for its Quo-Test A1C test.